Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Yate-Ching Yuan"'
Autor:
Jin Sun Lee, Susan Yost, Yujie Cui, Paul Frankel, Sierra Min Li, Yate-Ching Yuan, Denise Morse, Judy Wong-Toh, Linda Bosserman, Joanne Mortimer, Yuan Yuan
Publikováno v:
Cancer Research. 82:P5-13
Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are the standard of care for hormone receptor positive (HR+) metastatic breast cancer (MBC). Mechanisms of intrinsic and acquired resistances have been proposed but are poorly understood in
Autor:
Kevin M. Sullivan, Haiqing Li, Kelly Mahuron, Yate-Ching Yuan, Joseph Chao, Benjamin Paz, Haiyong Han, Yuman Fong, Yanghee Woo
Publikováno v:
Cancer Research. 82:6144-6144
Introduction: The infiltration or density of immunosuppressive or M2-macrophages has been correlated with worse prognosis in gastric cancer (GC). We hypothesized that a highly polarized transcriptional phenotype of M2 macrophages would be prognostic
Publikováno v:
Cancer Research. 82:898-898
Background: Colorectal cancer (CRC) remains the third most frequently diagnosed cancers in the United States. Current treatment modalities for patients with CRC include surgery, which is often followed with 5-fluorouracil (5FU) based adjuvant chemoth
Autor:
Zhen Han, Mingye Feng, Xiwei Wu, Chingyu Su, Yate-Ching Yuan, Hanjun Qin, James F. Sanchez, Jasmine Zain, Steven T. Rosen, Christiane Querfeld
Publikováno v:
Cancer Research. 82:5196-5196
Immune checkpoint (IC) blockade for programmed cell death 1 (PD1) and PD-Ligand 1 (PD-L1) has shown promising and durable therapeutic outcomes in cutaneous T-cell lymphoma (CTCL), but resistance and/or relapses are common. While research focused on i
Autor:
J Waisman, Daniel Schmolze, Norma Martinez, Aileen Tang, G. Somlo, Susan E. Yost, Peter P. Lee, S Apple, B Mendez, Mina S. Sedrak, Joanne E. Mortimer, N Tank, Paul Frankel, Timothy W. Synold, Yate-Ching Yuan, Arti Hurria
Publikováno v:
Cancer Research. 78:OT1-05
Background: Androgen receptor (AR) targeted therapy and immunotherapy represent one of the most promising strategies for metastatic triple negative breast cancer (mTNBC), which accounts for 15-20% of all breast cancers. As a nonsteroidal selective an
Autor:
Y Yuan, Yate-Ching Yuan, Zheng Liu, Joanne E. Mortimer, Paul Frankel, Susan E. Yost, S Nicola
Publikováno v:
Cancer Research. 77:P6-16
Background: Next-Generation Sequencing (NGS) has made genomic mutation-driven cancer medicine feasible. Recognizing the importance of pathway and biomarker-driven personalized therapy for patients with metastatic breast cancer (MBC), we frequently su
Autor:
Susan E. Yost, Zheng Liu, Yate-Ching Yuan, Y Liang, Y Yuan, Angela Ying-Jian Li, Charles Warden, Peiguo G. Chu, Xiwei Wu, L Goldstein, Jerry Wang
Publikováno v:
Cancer Research. 77:P1-05
Background: Triple negative breast cancer (TNBC) is a heterogeneous disease with several molecular subtypes: basal-like1 (BL1), basal-like 2 (BL-2), mesenchymal(M), mesenchymal-stem-like(MSL), immune-modulatory(IM) and unclassified (UNC) Molecular ev
Autor:
Travis Y. Tu, Daniel Schmolze, Yate-Ching Yuan, Anthony Rosario, Roger Wang, Peiguo Chu, Susan E. Yost, T-F He, Peter P. Lee
Publikováno v:
Cancer Research. 78:P3-05
Background: Triple negative breast cancer (TNBC) is a heterogeneous disease with several molecular subtypes: basal-like1 (BL-1), basal-like 2 (BL-2), mesenchymal (M), and luminal androgen receptor (LAR). Molecular evolution of TNBC through chemothera
Autor:
Timothy W. Synold, Jun Wu, Yate Ching Yuan, David Horne, M.L. Richard Yip, Bingsen Zhou, D. Lynne Smith, Shuya Hu, Leila Su, Weidong Hu, Shikha Gaur, Yun Yen
Publikováno v:
Cancer Research. 73:6484-6493
Ribonucleotide reductase (RNR) is an attractive target for anticancer agents given its central function in DNA synthesis, growth, metastasis, and drug resistance of cancer cells. The current clinically established RNR inhibitors have the shortcomings
Autor:
Sofia Loera, Xiwei Wu, Yate Ching Yuan, Kevin C. Chu, Yun Yen, Hanlin Gao, Jinhui Wang, Kimberley Ho, Frank Un, Yafan Wang, Peiguo Chu, Keqiang Zhang, Warren Chow
Publikováno v:
Cancer Research. 73:1298-1307
Fibroblast growth factor (FGF) receptor (FGFR) substrate 2 (FRS2) is an adaptor protein that plays a critical role in FGFR signaling. FRS2 is located on chromosome 12q13-15 that is frequently amplified in liposarcomas. The significance of FRS2 and FG